October 01, 2014 4:53 AM ET

Biotechnology

Company Overview of Idenix Pharmaceuticals Inc.

Executive Profile

Anthony Rosenberg

Former Head of Transplantation & Immunology, Novartis AG
AgeTotal Calculated CompensationThis person is connected to 1 Board Members in 1 different organizations across 2 different industries.

See Board Relationships
60--

Background

Mr. Anthony Rosenberg, also known as Tony, has been Head of Business Development and Licensing, since 2005 at Novartis AG. He served as Head of Transplantation & Immunology at Novartis AG from 2001 to April 1,2005. Mr. Rosenberg was global head of the transplant and immunology business unit at Novartis from 2000 to 2005. He initially joined Sandoz in 1980. He served in Various leading positions with Sandoz UK. Mr. Rosenberg serves as a Director of Novartis Option Fund. ...

Corporate Headquarters

320 Bent Street
Cambridge, Massachusetts 02141

United States

Phone: 617-995-9800
Fax: 617-995-9801

Board Members Memberships

Director
2012-2014
Former Director

Education

MS
University Of London
BS
University of Leicester

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Alan George Lafley Chairman, Chief Executive Officer, President and Member of Proxy Committee
The Procter & Gamble Company
$6.4M
Ian C. Read Chairman, Chief Executive Officer and Chairman of Executive Committee
Pfizer Inc.
$1.8M
Kenneth C. Frazier Chairman and Chief Executive Officer
Merck & Co. Inc.
$1.5M
Severin Schwan Ph.D.Chief Executive Officer and Director
Roche Holding AG
$5.1M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Idenix Pharmaceuticals Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.